A deep dive into the dynamics of blockbuster drugs. Using data from Evaluate Pharma, Scrip surveys the existing field of these top-tier products, examines the role that multiple indications play and the time it takes to reach blockbuster status, and considers whether there is an advantage for in-house or external assets.